Compare EGY & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EGY | EVO |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 657.4M | 568.6M |
| IPO Year | 1996 | 2007 |
| Metric | EGY | EVO |
|---|---|---|
| Price | $5.32 | $1.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $9.45 | $4.48 |
| AVG Volume (30 Days) | ★ 1.3M | 64.6K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $359,272,000.00 | N/A |
| Revenue This Year | $31.64 | N/A |
| Revenue Next Year | $11.86 | $18.90 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.36 | $1.33 |
| 52 Week High | $6.72 | $3.87 |
| Indicator | EGY | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 34.04 | 46.24 |
| Support Level | $5.01 | $1.50 |
| Resistance Level | $5.68 | $1.61 |
| Average True Range (ATR) | 0.25 | 0.06 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 27.22 | 18.75 |
VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.